Exosome Diagnostics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Exosome Diagnostics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 2 completed upper quartile by trial count

Exosome Diagnostics: 3 sponsored US clinical trials, none currently recruiting.

Exosome Diagnostics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Cancer Of Prostate, with 1 trials.

Upper-quartile sponsor footprint

Exosome Diagnostics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

3 total, page 1 of 1

COMPLETED

Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

NCT04720599
TERMINATED

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

NCT04357717
COMPLETED

Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)

NCT03031418

Therapeutic Areas

Cancer Of Prostate 1

How the Exosome Diagnostics archive is shaped

3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Cancer Of Prostate (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Exosome Diagnostics: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Exosome Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Exosome Diagnostics10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Exosome Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Exosome Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Exosome Diagnostics page

3 registered trials is a research-attention snapshot, not an endorsement of Exosome Diagnostics or any single study.

  • None of Exosome Diagnostics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Cancer Of Prostate is the condition Exosome Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer Of Prostate trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Exosome Diagnostics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.